DOHA: Qatar Biobank has appointed a leading industry expert, Dr Hadi Abderrahim (pictured) as its Managing Director to continue the drive for research into medical conditions that prevail in Qatar.
As a biotech and pharmaceutical executive with 18 years’ experience in biomarker development, turning biological discoveries into drugs and medical devices that can be used in the treatment of patients, and studying the effect of genetic factors on reactions to drugs and personalised medicine, Dr Abderrrahim will provide exceptional leadership to the growing Qatar Biobank team.
Dr Abderrahim’s commendable career includes founding GBM Consulting, a biotech strategy firm, consulting on clinical trials and business development.
As Head of Genetics and Biomarkers at renowned Merck Serono, the $5bn plus, revenue-earning pharmaceutical company based in Geneva, Dr Abderrahim oversaw a team of 40 and established a central Biobank based in Italy. Prior to that, as Head of Genetics and Genomics Platforms at Genset in Paris, Dr Abderrahim set up a genetics and pharmacogenetic team, improving on sample testing and processing. He obtained his MD speciality in Human Genetics from the prestigious Hopital Necker, Paris, and he has a PhD in Human Genetics and an executive MBA from HEC in Paris. The Peninsula
